AFT gains Australian registration for intravenous Maxigesic

AFT Pharmaceuticals says it has successfully registered the intravenous form of its Maxigesic medication with Australia’s Therapeutic Goods Administration.

The intravenous product contains 1,000 milligrams of paracetamol and 300mg of ibuprofen in a 100 millilitre solution.

The company says it expects to sell the product in Australia during the year ending March 2020 and the registration “clears the way for regulatory filings in a number of other territories including but not limited to Mexico, South East Asia, Korea and the Middle East, all of which rely upon registration by key global reference regulators such as the TGA in Australia.”

AFT says the product is designed for post-operative pain relief for patients who can’t take oral pain relief.

(BusinessDesk)

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

Sky TV cans dividend, writes off $670m ahead of rights battle
Ebos annual result flat as M&A costs hit bottom line
FIRST CUT: Auckland Airport earnings at top end of guidance
Are Fletcher's NZ earnings at the top of the cycle?
NZ dollar hovers near 64 US cents as central bankers gather
22nd August 2019 Morning Report
Hodson to stamp mark on new Spark strategy early next year
MARKET CLOSE: NZ shares sink as investors punish A2 over margins
NZ dollar falls against Aussie; RBNZ seen as more dovish than RBA
Air NZ CFO named acting chief executive